Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
As of close of business last night, Blueprint Medicines Corp’s stock clocked out at $108.34, down -0.40% from its previous closing price of $108.78. In other words, the price has decreased by -$0.40 from its previous closing price. On the day, 0.55 million shares were traded. BPMC stock price reached its highest trading level at $109.87 during the session, while it also had its lowest trading level at $107.9975.
Ratios:
To gain a deeper understanding of BPMC’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.61 and its Current Ratio is at 3.76. In the meantime, Its Debt-to-Equity ratio is 1.92 whereas as Long-Term Debt/Eq ratio is at 1.64.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Leerink Partners on May 06, 2024, Upgraded its rating to Market Perform and sets its target price to $97 from $50 previously.
On October 27, 2023, Oppenheimer Upgraded its rating to Outperform which previously was Perform but kept the price unchanged to $85.
Needham reiterated its Buy rating for the stock on August 21, 2023, while the target price for the stock was revised from $65 to $66.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on May 02 ’24 when Landsittel Michael sold 10,000 shares for $105.00 per share. The transaction valued at 1,050,000 led to the insider holds 47,286 shares of the business.
Hurley Ariel sold 1,834 shares of BPMC for $190,516 on May 02 ’24. The PRINCIPAL ACCOUNTING OFFICER now owns 14,913 shares after completing the transaction at $103.88 per share. On Mar 28 ’24, another insider, Landsittel Michael, who serves as the CHIEF FINANCIAL OFFICER of the company, sold 5,000 shares for $95.00 each. As a result, the insider received 475,000 and left with 47,286 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BPMC now has a Market Capitalization of 6783914496 and an Enterprise Value of 6761498624. For the stock, the TTM Price-to-Sale (P/S) ratio is 24.04 while its Price-to-Book (P/B) ratio in mrq is 21.83. Its current Enterprise Value per Revenue stands at 23.959 whereas that against EBITDA is -15.794.
Stock Price History:
The Beta on a monthly basis for BPMC is 0.69, which has changed by 1.0366971 over the last 52 weeks, in comparison to a change of 0.25590587 over the same period for the S&P500. Over the past 52 weeks, BPMC has reached a high of $110.93, while it has fallen to a 52-week low of $43.89. The 50-Day Moving Average of the stock is 17.19%, while the 200-Day Moving Average is calculated to be 50.23%.
Shares Statistics:
It appears that BPMC traded 823.89K shares on average per day over the past three months and 856210 shares per day over the past ten days. A total of 62.62M shares are outstanding, with a floating share count of 61.16M. Insiders hold about 2.33% of the company’s shares, while institutions hold 103.71% stake in the company. Shares short for BPMC as of 1713139200 were 4245492 with a Short Ratio of 5.15, compared to 1710460800 on 5151094. Therefore, it implies a Short% of Shares Outstanding of 4245492 and a Short% of Float of 7.62.
Earnings Estimates
The dynamic stock of Blueprint Medicines Corp (BPMC) is currently being evaluated by a team of 15.0 analysts, each contributing to its current rating.On average, analysts expect EPS of -$1.29 for the current quarter, with a high estimate of -$1.07 and a low estimate of -$1.53, while EPS last year was -$2.19. The consensus estimate for the next quarter is -$1.16, with high estimates of -$0.87 and low estimates of -$1.46.
Analysts are recommending an EPS of between -$1.1 and -$3.96 for the fiscal current year, implying an average EPS of -$2.32. EPS for the following year is -$1.38, with 15.0 analysts recommending between $1.71 and -$3.59.
Revenue Estimates
In the current quarter, 15 analysts expect revenue to total $103.33M. It ranges from a high estimate of $116M to a low estimate of $98M. As of the current estimate, Blueprint Medicines Corp’s year-ago sales were $45.47MFor the next quarter, 15 analysts are estimating revenue of $112.7M. There is a high estimate of $132.2M for the next quarter, whereas the lowest estimate is $105.1M.
A total of 17 analysts have provided revenue estimates for BPMC’s current fiscal year. The highest revenue estimate was $495M, while the lowest revenue estimate was $410.2M, resulting in an average revenue estimate of $431.3M. In the same quarter a year ago, actual revenue was $249.38MBased on 17 analysts’ estimates, the company’s revenue will be $653.87M in the next fiscal year. The high estimate is $964M and the low estimate is $572.1M.
